Clinical TrialJun 11, 2026, 08:03 AM
Kura Oncology's Ziftomenib Trial Shows 94% OS in NPM1-m AML
AI Summary
Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced encouraging long-term results from the Phase 1/2 KOMET-007 trial evaluating ziftomenib in combination with intensive chemotherapy (7+3) for newly diagnosed NPM1-m or KMT2A-r AML. The trial demonstrated a 94% 12-month overall survival rate in NPM1-m AML patients and 71% in KMT2A-r AML patients, along with high composite complete remission rates of 96% and 90% respectively. These favorable results, including deep molecular responses and a manageable safety profile, strengthen confidence in the ongoing Phase 3 KOMET-017 registrational study. Kura Oncology will host a virtual investor event to discuss these findings.
Key Highlights
- Ziftomenib in KOMET-007 trial showed 94% 12-month OS rate in NPM1-m AML patients.
- Ziftomenib achieved 71% 12-month OS rate in KMT2A-r AML patients.
- 96% composite complete remission (CRc) in newly diagnosed NPM1-m AML patients.
- 90% CRc in newly diagnosed KMT2A-r AML patients.
- Median OS not reached in NPM1-m AML (17.6 months follow-up) or KMT2A-r AML (11.0 months follow-up).
- High rates of MRD negativity: 85% in NPM1-m AML and 82% in KMT2A-r AML by local assay.
- Ziftomenib 600 mg plus 7+3 showed a consistent and manageable safety profile.
- Kura Oncology will host a virtual investor event on June 12, 2026, at 8:00 a.m. ET.
Price Impact
More from KURA